Neurocrine Biosciences, Inc. (LON: 0K6R)
London
· Delayed Price · Currency is GBP · Price in USD
146.22
+1.60 (1.11%)
Jan 22, 2025, 7:14 PM BST
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,400 employees as of December 30, 2023. The number of employees increased by 200 or 16.67% compared to the previous year.
Employees
1,400
Change (1Y)
200
Growth (1Y)
16.67%
Revenue / Employee
984.33K GBP
Profits / Employee
169.36K GBP
Market Cap
12.06B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
ConvaTec Group | 10,136 |
Hikma Pharmaceuticals | 9,100 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Neurocrine Biosciences News
- 9 days ago - Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio - GlobeNewsWire
- 15 days ago - Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism - PRNewsWire
- 16 days ago - Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences Stock Sees RS Rating Upgrade - Investor's Business Daily
- 4 weeks ago - Neurocrine Biosciences Announces U.S. Launch of CRENESSITY for Classic Congenital Adrenal ... - GuruFocus
- 4 weeks ago - Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PRNewsWire
- 5 weeks ago - Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth - Seeking Alpha
- 5 weeks ago - Neurocrine wins FDA nod for CAH therapy - Seeking Alpha